Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: Results of 7 children from a cohort of 86

Child's Nervous System

Volumn 30, Issue 2, 2014, Pages 227-240

  Canpolat, Mehmet ^a   Per, Huseyin ^a   Gumus, Hakan ^a   Yikilmaz, Ali ^a   Unal, Ekrem ^a   Patiroglu, Turkan ^a   Cinar, Levent ^b   Kurtsoy, Ali ^a   Kumandas, Sefer ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b Kayseri State Hospital of Research and Education   (Turkey)

Author keywords

Children; Epilepsy; Rapamycin; Tuberous sclerosis complex

Indexed keywords

ANTIBIOTICS, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 84893959443     PISSN: 02567040     EISSN: 14330350     Source Type: Journal    
DOI: 10.1007/s00381-013-2185-6     Document Type: Article

References (73)

1. Jansen FE, van Nieuwenhuizen O, van Huffelen AC (2004) Tuberous sclerosis complex and its founders. J Neurol Neurosurg Psychiatry 75:770
2. Baskin HJ Jr (2008) The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol 38:936-952
3. Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372:657-668
4. Roach ES, Gomez MR, Northrup H (1998) Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 13:624-628
5. Hyman MH, Whittemore VH (2000) National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662-665
6. Roach ES, Sparagana SP (2004) Diagnosis of tuberous sclerosis complex. J Child Neurol 19:643-649
7. Au KS, Williams AT, Roach ES et al (2007) Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 9:88-100
8. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA (2010) The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51:1236-1241
9. European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315
10. van Slegtenhorst M, de Hoogt R, Hermans C et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-808
11. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578-581
12. Gong R, Park CS, Abbassi NR, Tang SJ (2006) Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem 281:18802-18815
13. Raab-Graham KF, Haddick PC, Jan YN, Jan LY (2006) Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science 314:144-148
14. Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL (2005) Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 8:1727-1734
15. Inoki K, Guan KL (2006) Complexity of the TOR signaling network. Trends Cell Biol 16:206-212
16. Franz DN, Bissler JJ, McCormack FX (2010) Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics 41:199-208
17. Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345-1356
18. Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28:721-726
19. Augustine JJ, Bodziak KA, Hricik DE (2007) Use of sirolimus in solid organ transplantation. Drugs 67:369-391
20. Herry I, Neukirch C, Debray MP, Mignon F, Crestani B (2007) Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 18:76-77
21. Franz DN, Leonard J, Tudor C et al (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490-498
22. Hofbauer GF, Marcollo-Pini A, Corsenca A et al (2008) The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 159:473-475
23. Micozkadioglu H, Koc Z, Ozelsancak R, Yildiz I (2010) Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient. Ren Fail 32:1233-1236
24. Zeng LH, Rensing NR, Wong M (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29:6964-6972
25. Zeng LH, Xu L, Gutmann DH, Wong M (2008) Rapamycin prevents epilepsy in a Mouse model of tuberous sclerosis complex. Ann Neurol 63:444-453
26. Muncy J, Butler IJ, Koenig MK (2009) Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 24:477
27. Ekici MA, Kumandas S, Per H et al (2011) Surgical timing of the subependymal giant cell astrocytoma (SEGA) with the patients of tuberous sclerosis complex. Turk Neurosurg 21:315-324
28. Bolton PF, Park RJ, Higgins JN, Griffiths PD, Pickles A (2002) Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 125:1247-1255
29. Joinson C, O'Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF (2003) Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 33:335-344
30. Jozwiak S, Goodman M, Lamm SH (1998) Poor mental development in patients with tuberous sclerosis complex: clinical risk factors. Arch Neurol 55:379-384
31. Goh S, Kwiatkowski DJ, Dorer DJ, Thiele EA (2005) Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 65:235-238
32. Jambaque I, Chiron C, Dumas C, Mumford J, Dulac O (2000) Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 38:151-160
33. Chou IJ, Lin KL, Wong AM et al (2008) Neuroimaging correlation with neurological severity in tuberous sclerosis complex. Eur J Paediatr Neurol 12:108-112
34. Inoue Y, Nemoto Y, Murata R et al (1988) CT and MR imaging of cerebral tuberous sclerosis. Brain Dev 20:209-221
35. Luat AF, Makki M, Chugani HT (2007) Neuroimaging in tuberous sclerosis complex. Curr Opin Neurol 20:142-150
36. Michelozzi C, Di Leo G, Galli F et al (2013) Subependymal nodules and giant cell tumours in tuberous sclerosis complex patients: prevalence on MRI in relation to gene mutation. Childs Nerv Syst 29:249-254
37. Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C (1999) Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 66:370-375
38. Rüegg S, Baybis M, Juul H, Dichter M, Crino PB (2007) Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res 77:85-92
39. Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL (2003) Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 19:232-243
40. Bissler JJ, McCormack FX, Young LR et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151
41. Atalay S, Aypar E, Uçar T et al (2010) Fetal and neonatal cardiac rhabdomyomas: clinical presentation, outcome and association with tuberous sclerosis complex. Turk J Pediatr 52:481-487
42. Thiele E (2004) Managing epilepsy in tuberous sclerosis complex. J Child Neurol 19:680-686
43. Levine NB, Collins J, Franz DN, Crone KR (2006) Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim Invasive Neurosurg 49:317-320
44. Manuchehri K, Goodman S, Siviter L, Nightingale S (2008) A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84:499-505
45. Lawden MC, Eke T, Degg C, Harding GF, Wild JM (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716-722
46. Buoni S, Zannolli R, Strambi M, Fois A (2004) Combined treatment with vigabatrin and topiramate in West syndrome. J Child Neurol 19:385-386
47. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS (2011) A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 43:322-329
48. Kossoff EH, Thiele EA, Pfeifer HH, McGrogan JR, Freeman JM (2005) Tuberous sclerosis complex and the ketogenic diet. Epilepsia 46:1684-1686
49. Wong M (2011) Rapamycin for treatment of epilepsy: antiseizure, antiepileptogenic, both, or neither? Epilepsy Curr 11:66-68
50. Buckmaster PS, Ingram EA, Wen X (2009) Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J Neurosci 29:8259-8269
51. Sliwa A, Plucinska G, Bednarczyk J, Lukasiuk K (2012) Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci Lett 509:105-109
52. Galanopoulou AS, Buckmaster PS, Staley KJ et al (2012) American Epilepsy Society Basic Science Committee and The International League Against Epilepsy Working Group on Recommendations for Preclinical Epilepsy Drug Discovery. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571-582
53. Ljungberg MC, Sunnen CN, Lugo JN, Anderson AE, D'Arcangelo G (2009) Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2:389-398
54. Zhou J, Blundell J, Ogawa S et al (2009) Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci 29:1773-1783
55. Huang X, Zhang H, Yang J et al (2010) Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 40:193-199
56. Galanopoulou AS, Gorter JA, Cepeda C (2012) Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 53:1119-1130
57. + channel is modulated by FK506 and rapamycin. Brain Res 786:255-258
58. Wang Y, Barbaro MF, Baraban SC (2006) A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci Lett 401:35-39
59. Ruan B, Pong K, Jow F et al (2008) Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci USA 105:33-38
60. Daoud D, Scheld HH, Speckmann EJ, Gorji A (2007) Rapamycin: brain excitability studied in vitro. Epilepsia 48:834-836
61. Cepeda C, Andre VM, Hauptman JS et al (2012) Enhanced GABAergic network and receptor function in pediatric cortical dysplasia Type IIB compared with Tuberous Sclerosis Complex. Neurobiol Dis 45:310-321
62. Wong M (2010) Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 51:27-36
63. Wong M (2011) Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Exp Neurol 244:22-26
64. Krueger DA, Care MM, Holland K et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801-1811
65. Rosser T, Panigrahy A, McClintock W (2006) The diverse clinical manifestations of tuberous sclerosis complex: a review. Semin Pediatr Neurol 13:27-36
66. Prather P, de Vries PJ (2004) Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol 19:666-674
67. McCullough DL, Scott R Jr, Seybold HM (1971) Renal angiomyolipoma (hamartoma): review of the literature and report of 7 cases. J Urol 105:32-44
68. Stillwell TJ, Gomez MR, Kelalis PP (1987) Renal lesions in tuberous sclerosis. J Urol 138:477-481
69. Steiner MS, Goldman SM, Fishman EK, Marshall FF (1993) The natural history of renal angiomyolipoma. J Urol 150:1782-1786
70. Casper KA, Donnelly LF, Chen B, Bissler JJ (2002) Tuberous sclerosis complex: renal imaging findings. Radiology 225:451-456
71. Cabrera Lopez C, Marti T, Catala V et al (2011) Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis. Nefrologia 31:292-298
72. Truchuelo T, Díaz-Ley B, Ríos L, Alcántara J, Jaén P (2012) Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Dermatol Online J 18:15
73. Rauktys A, Lee N, Lee L, Dabora SL (2008) Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 8:1